TrialEuropean heart journal2009

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.

Christoph Varenhorst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.